A 71-year-old woman with severe COPD (FEV1 38% predicted) is admitted with her third exacerbation requiring hospitalization in 12 months. She is currently on fluticasone/vilanterol 92/22 micrograms once daily and tiotropium 18 micrograms once daily. She is a lifelong non-smoker. Her body mass index is 18.5 kg/m². Full blood count shows haemoglobin 178 g/L, haematocrit 0.54. Oxygen saturations are 91% on room air. Which additional investigation would be most important to arrange following recovery from this acute exacerbation?
Q52
A 39-year-old man who works in a bakery presents with episodic wheeze, chest tightness, and breathlessness that improves when he is on holiday. He has no symptoms at weekends. Peak flow monitoring shows: Monday-Friday average 420 L/min (best 480 L/min), weekend/holiday average 465 L/min (best 480 L/min). Spirometry on a Friday afternoon shows FEV1 72% predicted with 18% reversibility. Skin prick testing is positive to flour dust. What is the most appropriate immediate advice regarding his employment?
Q53
A 57-year-old man is admitted with community-acquired pneumonia. On admission, he has: respiratory rate 26/min, blood pressure 125/75 mmHg, heart rate 98 bpm, temperature 38.5°C, oxygen saturation 93% on room air, alert and oriented. Blood tests show: urea 5.2 mmol/L, CRP 185 mg/L, white cell count 16.8 × 10⁹/L. Chest X-ray shows right lower lobe consolidation. He is started on appropriate antibiotics and oxygen therapy. According to the CURB-65 score, what is his predicted mortality risk and most appropriate initial management location?
Q54
A 43-year-old woman presents to her GP with a 4-month history of dry cough and breathlessness, particularly noticeable when laughing or exercising. She has no past medical history and is a non-smoker. Physical examination is unremarkable with normal chest auscultation. Spirometry shows FEV1 2.8L (92% predicted), FVC 3.4L (95% predicted), FEV1/FVC ratio 0.82. A bronchodilator reversibility test shows a 6% improvement in FEV1. What is the most appropriate next investigation to establish the diagnosis?
Q55
A 66-year-old woman presents to the Emergency Department with a 3-day history of increasing breathlessness, productive cough with green sputum, and wheeze. She has known COPD and is normally on tiotropium and salbutamol inhalers. On examination, temperature 37.8°C, respiratory rate 28/min, heart rate 105 bpm, blood pressure 135/80 mmHg, oxygen saturation 88% on room air. Arterial blood gas on 28% oxygen shows: pH 7.33, PaO2 9.2 kPa, PaCO2 7.8 kPa, HCO3- 32 mmol/L, BE +4. Chest X-ray shows hyperinflation but no focal consolidation. She is started on nebulised bronchodilators, prednisolone, and antibiotics. What is the most appropriate next step in her respiratory management?
Q56
A 59-year-old man with a 40 pack-year smoking history presents to his GP with a 9-month history of productive cough and breathlessness on climbing stairs. He continues to smoke 15 cigarettes daily. Spirometry performed in the surgery shows FEV1 1.9L (62% predicted), FVC 3.2L (78% predicted), and FEV1/FVC ratio of 0.59. He has no other significant medical history. What is the most appropriate initial pharmacological management?
Q57
A 48-year-old woman with poorly controlled asthma attends respiratory clinic. She is currently using beclometasone 400 micrograms twice daily, salmeterol 50 micrograms twice daily, montelukast 10mg once daily, and salbutamol as needed. Her ACQ-5 score is 2.8, she wakes at night three times per week, and has had three courses of oral prednisolone in the past year. Spirometry shows FEV1 68% predicted with 15% reversibility. Blood eosinophil count is 520 cells/microlitre. What is the most appropriate next step in her management according to current guidelines?
Q58
A 34-year-old nurse presents to the Emergency Department with a 2-hour history of worsening breathlessness and wheeze. She has a history of asthma and uses beclometasone 200 micrograms twice daily and salbutamol as required. On examination, she is unable to complete sentences, her respiratory rate is 32/min, heart rate 125 bpm, oxygen saturation 90% on room air, and PEFR is 35% of her best. She has widespread wheeze bilaterally. She is treated with oxygen, nebulised salbutamol and ipratropium, and oral prednisolone. What is the most appropriate next step in management?
Q59
A 52-year-old woman presents with a 5-day history of productive cough, fever, and right-sided pleuritic chest pain. She has no comorbidities. Observations: temperature 38.2°C, HR 92/min, BP 128/76 mmHg, RR 20/min, SpO2 96% on air. She is alert (AMT 10/10). Blood tests show urea 5.8 mmol/L. Chest X-ray confirms right middle lobe consolidation. According to NICE guidelines, what is the most appropriate initial antibiotic treatment?
Q60
A 71-year-old man with known COPD (FEV1 40% predicted) on home oxygen presents with acute confusion, drowsiness, and headache. His wife reports he increased his oxygen from 2L/min to 6L/min this morning due to increased breathlessness. Observations: GCS 13 (E3, V4, M6), RR 12/min, HR 88/min, BP 145/82 mmHg. Arterial blood gas on 6L/min oxygen shows: pH 7.19, PaCO2 9.8 kPa, PaO2 13.2 kPa, HCO3- 35 mmol/L, BE +8. What is the most important immediate management step?
Respiratory Medicine UK Medical PG Practice Questions and MCQs
Question 51: A 71-year-old woman with severe COPD (FEV1 38% predicted) is admitted with her third exacerbation requiring hospitalization in 12 months. She is currently on fluticasone/vilanterol 92/22 micrograms once daily and tiotropium 18 micrograms once daily. She is a lifelong non-smoker. Her body mass index is 18.5 kg/m². Full blood count shows haemoglobin 178 g/L, haematocrit 0.54. Oxygen saturations are 91% on room air. Which additional investigation would be most important to arrange following recovery from this acute exacerbation?
A. CT chest to exclude bronchiectasis or underlying malignancy
B. Arterial blood gas on room air to assess for chronic hypercapnia
C. Alpha-1 antitrypsin level (Correct Answer)
D. Echocardiography to assess for pulmonary hypertension
E. Sleep study to exclude obstructive sleep apnoea
Explanation: ***Alpha-1 antitrypsin level***- This patient is a **lifelong non-smoker** with severe COPD and a **low BMI**, which are clinical red flags for **Alpha-1 antitrypsin deficiency (AATD)** regardless of the patient's age.- Guidelines recommend a one-time screening for **AATD** in all patients diagnosed with COPD to identify genetic risk and facilitate family screening or targeted management.*CT chest to exclude bronchiectasis or underlying malignancy*- While a CT is useful for evaluating **bronchiectasis** or nodules in smokers, it does not address the underlying etiology of severe airflow obstruction in a **non-smoker**.- Investigating the genetic cause takes precedence in a non-smoker with severe disease presentation to guide long-term prognosis.*Arterial blood gas on room air to assess for chronic hypercapnia*- ABGs are used to assess the need for **Long-term Oxygen Therapy (LTOT)** or to detect **Type 2 respiratory failure**, but they do not provide a primary diagnosis for the lung disease.- While her **secondary polycythaemia** (Hb 178 g/L) suggests chronic hypoxia, it is a consequence of the disease rather than the underlying cause.*Echocardiography to assess for pulmonary hypertension*- Echocardiography identifies **cor pulmonale** or **pulmonary hypertension** resulting from chronic lung disease, but it is not a diagnostic tool for the lung pathology itself.- This is a supportive investigation for complications rather than a workup for the **etiology** of COPD in a non-smoker.*Sleep study to exclude obstructive sleep apnoea*- A sleep study would investigate **overlap syndrome**, but the patient's **low BMI (18.5 kg/m²)** makes obstructive sleep apnoea less likely compared to other causes.- Detecting genetic factors like **AATD** is more critical for a non-smoker presenting with severe emphysematous-type disease.
Question 52: A 39-year-old man who works in a bakery presents with episodic wheeze, chest tightness, and breathlessness that improves when he is on holiday. He has no symptoms at weekends. Peak flow monitoring shows: Monday-Friday average 420 L/min (best 480 L/min), weekend/holiday average 465 L/min (best 480 L/min). Spirometry on a Friday afternoon shows FEV1 72% predicted with 18% reversibility. Skin prick testing is positive to flour dust. What is the most appropriate immediate advice regarding his employment?
A. Continue working with current exposure but use FFP3 respirator mask
B. Request redeployment to area with no flour exposure if possible (Correct Answer)
C. Resign from employment immediately and seek alternative work
D. Continue current role and commence high-dose inhaled corticosteroids
E. Reduce working hours to part-time to minimize exposure
Explanation: ***Request redeployment to area with no flour exposure if possible***- The gold standard for management of **occupational asthma** (baker's asthma in this case) is the **complete avoidance** of the causative agent (flour dust) to prevent permanent lung damage.- **Redeployment** is the preferred first step as it removes the patient from the trigger while maintaining their **employment status** and financial security.*Continue working with current exposure but use FFP3 respirator mask*- **Personal Protective Equipment (PPE)** is considered a secondary control measure and is often **ineffective** in preventing asthma exacerbations once sensitization has occurred.- Masks can have poor fit-testing or be removed during the shift, offering **insufficient protection** against inhaled allergens that trigger a hyper-reactive airway.*Resign from employment immediately and seek alternative work*- Immediate resignation is considered premature and an **extreme measure** if there are options for the employer to provide a safe, allergen-free worksite.- Legal and occupational guidelines advise exploring **reasonable adjustments** and redeployment before ending a contract of employment.*Continue current role and commence high-dose inhaled corticosteroids*- Managing symptoms with **pharmacotherapy** while maintaining exposure is inappropriate as the underlying inflammation will cause **progressive decline** in lung function.- **Inhaled corticosteroids** do not address the root cause and cannot bypass the immune-mediated response triggered by daily allergen exposure.*Reduce working hours to part-time to minimize exposure*- There is no "safe" lower limit of exposure once a patient is **sensitized**; even small amounts of flour dust can trigger a severe asthmatic response.- **Part-time work** still results in repeated inflammatory insults to the airways, leading to **chronic asthma** and potential long-term disability.
Question 53: A 57-year-old man is admitted with community-acquired pneumonia. On admission, he has: respiratory rate 26/min, blood pressure 125/75 mmHg, heart rate 98 bpm, temperature 38.5°C, oxygen saturation 93% on room air, alert and oriented. Blood tests show: urea 5.2 mmol/L, CRP 185 mg/L, white cell count 16.8 × 10⁹/L. Chest X-ray shows right lower lobe consolidation. He is started on appropriate antibiotics and oxygen therapy. According to the CURB-65 score, what is his predicted mortality risk and most appropriate initial management location?
A. Mortality <1%, suitable for home treatment with oral antibiotics
B. Mortality 1-2%, consider hospital admission for short stay (Correct Answer)
C. Mortality 3-15%, recommend hospital admission
D. Mortality >15%, consider intensive care assessment
E. Mortality 9-15%, mandatory intensive care admission
Explanation: ***Mortality 1-2%, consider hospital admission for short stay*** - The patient has a **CURB-65 score of 1**. This is primarily due to the **respiratory rate of 26/min**, which, while traditionally requiring ≥30/min for 1 point, is often considered a significant clinical indicator warranting closer monitoring, and is sometimes assigned a point in clinical assessments or modified scoring systems. - Despite a score that might strictly be 0, the need for **oxygen therapy** (SpO2 93% on room air) and a significantly elevated **CRP (185 mg/L)** are additional markers of severity, making **hospital admission** for a short stay the most appropriate initial management, aligning with the 1-2% mortality risk for a CURB-65 score of 1. *Mortality <1%, suitable for home treatment with oral antibiotics* - This option corresponds to a **CURB-65 score of 0**, which typically indicates very low risk and suitability for outpatient management. - However, the patient's requirement for **supplemental oxygen** and high **CRP** demonstrate a more severe presentation, making home treatment unsuitable. *Mortality 3-15%, recommend hospital admission* - This risk level is associated with a **CURB-65 score of 2**, indicating moderate severity and a clear recommendation for hospital admission. - The patient's score, based on the respiratory rate alone (assuming 1 point for 26/min), is 1, not reaching the criteria for a score of 2 (which would require another parameter like confusion or elevated urea). *Mortality >15%, consider intensive care assessment* - This severe classification is reserved for patients with **CURB-65 scores of 3 to 5**, indicating a high risk of mortality and necessitating urgent hospital admission and consideration for ICU. - This patient does not exhibit the critical features of confusion, hypotension, or severe uremia that would elevate the score to this high-risk category. *Mortality 9-15%, mandatory intensive care admission* - Mandatory ICU admission is indicated for patients with severe physiological compromise or those needing **vasopressors** or **mechanical ventilation**, typically associated with very high CURB-65 scores (4-5) or major criteria for severe CAP. - Despite localized consolidation, this patient's **hemodynamics are stable** (BP 125/75 mmHg) and he remains alert and oriented, not meeting criteria for mandatory ICU admission.
Question 54: A 43-year-old woman presents to her GP with a 4-month history of dry cough and breathlessness, particularly noticeable when laughing or exercising. She has no past medical history and is a non-smoker. Physical examination is unremarkable with normal chest auscultation. Spirometry shows FEV1 2.8L (92% predicted), FVC 3.4L (95% predicted), FEV1/FVC ratio 0.82. A bronchodilator reversibility test shows a 6% improvement in FEV1. What is the most appropriate next investigation to establish the diagnosis?
A. Fractional exhaled nitric oxide (FeNO) testing (Correct Answer)
B. Peak flow diary for 2-4 weeks
C. Chest X-ray
D. CT pulmonary angiogram
E. Trial of inhaled corticosteroid therapy
Explanation: ***Fractional exhaled nitric oxide (FeNO) testing***
- In a patient with suspected asthma (cough and breathlessness worsened by activity) but normal spirometry and a negative **bronchodilator reversibility (BDR)** test, **FeNO testing** is the recommended next step by guidelines (e.g., NICE) to detect **eosinophilic airway inflammation**.
- An elevated FeNO level (typically **≥40 ppb** in adults) provides objective evidence supporting the diagnosis of **asthma**, even in the absence of spirometric obstruction or reversibility.
*Peak flow diary for 2-4 weeks*
- While a peak flow diary can identify **diurnal variability** in airflow, which is suggestive of asthma, it is a less objective measure compared to **FeNO testing** and often relies on patient adherence.
- **NICE guidelines** prioritize objective measures of airway inflammation (FeNO) or hyperreactivity (bronchial challenge) over peak flow monitoring as the primary diagnostic step when spirometry is normal.
*Chest X-ray*
- A chest X-ray is primarily useful for ruling out other respiratory conditions like **pneumonia**, **interstitial lung disease**, or **malignancy**.
- Given the patient's normal physical examination, chronic intermittent symptoms, and absence of alarm features, a chest X-ray is unlikely to aid in the specific diagnosis of **asthma** and is not the most appropriate next step.
*CT pulmonary angiogram*
- **CT pulmonary angiogram (CTPA)** is the gold standard for diagnosing **pulmonary embolism (PE)**, which typically presents with acute onset dyspnea, pleuritic chest pain, and often tachycardia.
- The patient's 4-month history of a dry cough and breathlessness specifically exacerbated by laughing or exercise is inconsistent with the typical presentation of an acute **PE**.
*Trial of inhaled corticosteroid therapy*
- Initiating a **trial of inhaled corticosteroids (ICS)** as a diagnostic tool is generally discouraged by guidelines (e.g., NICE) because it can mask symptoms without providing a definitive physiological diagnosis.
- Objective tests like **FeNO** or **bronchial challenge testing** should be performed first to confirm the diagnosis of **asthma** before committing to long-term treatment.
Question 55: A 66-year-old woman presents to the Emergency Department with a 3-day history of increasing breathlessness, productive cough with green sputum, and wheeze. She has known COPD and is normally on tiotropium and salbutamol inhalers. On examination, temperature 37.8°C, respiratory rate 28/min, heart rate 105 bpm, blood pressure 135/80 mmHg, oxygen saturation 88% on room air. Arterial blood gas on 28% oxygen shows: pH 7.33, PaO2 9.2 kPa, PaCO2 7.8 kPa, HCO3- 32 mmol/L, BE +4. Chest X-ray shows hyperinflation but no focal consolidation. She is started on nebulised bronchodilators, prednisolone, and antibiotics. What is the most appropriate next step in her respiratory management?
A. Increase oxygen to achieve SpO2 94-98%
B. Commence bilevel positive airway pressure (BiPAP) ventilation (Correct Answer)
C. Continue current oxygen therapy targeting SpO2 88-92%
D. Intubate and mechanically ventilate
E. Commence continuous positive airway pressure (CPAP)
Explanation: ***Commence bilevel positive airway pressure (BiPAP) ventilation***- The patient presents with **acute hypercapnic respiratory failure (Type 2)** characterized by **respiratory acidosis** (pH 7.33, PaCO2 7.8 kPa) despite initial medical management.- **Non-invasive ventilation (NIV), specifically BiPAP**, is indicated for COPD exacerbations with **acidosis (pH 7.25-7.35)** to reduce the work of breathing and improve gas exchange.*Increase oxygen to achieve SpO2 94-98%*- Administering **high-concentration oxygen** to COPD patients can suppress the **hypoxic drive** and worsen **hypercapnia** due to ventilation-perfusion mismatch.- The target oxygen saturation for patients at risk of **hypercapnic respiratory failure** (like this COPD patient) is **88-92%**.*Continue current oxygen therapy targeting SpO2 88-92%*- While maintaining oxygen saturation within the **88-92% target range** is appropriate for COPD, the presence of **acidosis (pH 7.33)** indicates that this alone is insufficient.- The patient's worsening acidosis despite initial therapy necessitates escalation to **non-invasive ventilation** to improve CO2 clearance.*Intubate and mechanically ventilate*- **Invasive mechanical ventilation** is typically reserved for patients with more severe **respiratory acidosis (pH < 7.25)**, those failing NIV, or those with altered mental status or impending respiratory arrest.- It carries significant risks, including **ventilator-associated pneumonia** and difficulty weaning, making it a last resort after NIV failure.*Commence continuous positive airway pressure (CPAP)*- **CPAP** provides a single, constant positive pressure and is primarily effective for conditions like **obstructive sleep apnea** or **Type 1 respiratory failure** (e.g., cardiogenic pulmonary edema).- It is less effective than BiPAP for **Type 2 respiratory failure** as it doesn't provide the inspiratory pressure support needed to augment ventilation and remove excess **CO2**.
Question 56: A 59-year-old man with a 40 pack-year smoking history presents to his GP with a 9-month history of productive cough and breathlessness on climbing stairs. He continues to smoke 15 cigarettes daily. Spirometry performed in the surgery shows FEV1 1.9L (62% predicted), FVC 3.2L (78% predicted), and FEV1/FVC ratio of 0.59. He has no other significant medical history. What is the most appropriate initial pharmacological management?
A. Short-acting beta-2 agonist (SABA) as required (Correct Answer)
B. Long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination
C. Inhaled corticosteroid (ICS) and LABA combination
D. LAMA monotherapy
E. SABA and short-acting muscarinic antagonist (SAMA) combination
Explanation: ***Short-acting beta-2 agonist (SABA) as required***- According to current guidelines (e.g., NICE, GOLD), the initial pharmacological treatment for a new diagnosis of **COPD** is a short-acting bronchodilator (either a **SABA** or a **SAMA**) for **symptom relief as required**.- This patient has a confirmed diagnosis of **COPD** with an obstructive defect and symptoms, making a **SABA** the most appropriate initial step for intermittent breathlessness and cough.*Long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination*- This **dual bronchodilation** is typically reserved for patients with more persistent or severe symptoms, or those experiencing exacerbations, after initial monotherapy with a long-acting agent.- It is generally not the initial pharmacological step for a newly diagnosed patient, as guidelines recommend a stepwise approach starting with short-acting agents.*Inhaled corticosteroid (ICS) and LABA combination*- **ICS/LABA** therapy is indicated for **COPD** patients with frequent **exacerbations** or those with features suggesting **asthma** overlap (e.g., high eosinophil count), which are not described in this case.- Routine use of **ICS** in **COPD** without these specific indications is discouraged due to an increased risk of side effects like **pneumonia**.*LAMA monotherapy*- While **LAMA monotherapy** is a common maintenance therapy for **COPD**, especially for patients with persistent symptoms, it is often introduced after an initial trial of short-acting bronchodilators.- Guidelines prioritize starting with a **short-acting bronchodilator** for
Question 57: A 48-year-old woman with poorly controlled asthma attends respiratory clinic. She is currently using beclometasone 400 micrograms twice daily, salmeterol 50 micrograms twice daily, montelukast 10mg once daily, and salbutamol as needed. Her ACQ-5 score is 2.8, she wakes at night three times per week, and has had three courses of oral prednisolone in the past year. Spirometry shows FEV1 68% predicted with 15% reversibility. Blood eosinophil count is 520 cells/microlitre. What is the most appropriate next step in her management according to current guidelines?
A. Increase inhaled corticosteroid dose to beclometasone 800 micrograms twice daily
B. Add theophylline to current therapy
C. Refer for consideration of biologic therapy (Correct Answer)
D. Add regular oral prednisolone 5mg daily
E. Switch to triple therapy with ICS/LABA/LAMA combination
Explanation: ***Refer for consideration of biologic therapy***
- This patient has **severe eosinophilic asthma** with a blood eosinophil count of 520 cells/microlitre and frequent exacerbations despite high-dose **ICS/LABA/LTRA** therapy.
- According to current guidelines, such patients should be referred for assessment for **biologic therapy** (e.g., anti-IL5, anti-IL5R, or anti-IgE) to improve control and reduce oral corticosteroid dependency.
*Increase inhaled corticosteroid dose to beclometasone 800 micrograms twice daily*
- The patient is already on a **high dose of ICS** (beclometasone 400mcg twice daily), and further escalation typically offers **diminishing returns** with increased risk of local and systemic side effects.
- Guidelines recommend considering other add-on therapies or biologics when asthma remains uncontrolled on high-dose ICS/LABA plus LTRA or other controller.
*Add theophylline to current therapy*
- **Theophylline** is a less preferred add-on therapy due to its **narrow therapeutic window**, significant **side-effect profile**, and potential for **drug interactions**.
- In patients with severe eosinophilic asthma, more targeted therapies like **biologics** are far more effective at achieving disease control than xanthine derivatives.
*Add regular oral prednisolone 5mg daily*
- **Maintenance oral corticosteroids** should be avoided whenever possible due to their severe and numerous **long-term systemic side effects** (e.g., osteoporosis, diabetes, cataracts, adrenal suppression).
- The aim of modern severe asthma management is to reduce or eliminate the need for **systemic steroids**, making biologic therapy a safer and more effective alternative.
*Switch to triple therapy with ICS/LABA/LAMA combination*
- While adding a **LAMA** is an appropriate step in some patients with uncontrolled asthma, this patient's high **eosinophil count** and frequent exacerbations strongly indicate an eosinophilic phenotype.
- For severe eosinophilic asthma, **biologic therapy** is generally considered a more potent and targeted intervention to achieve control and reduce exacerbations than simply adding a LAMA.
Question 58: A 34-year-old nurse presents to the Emergency Department with a 2-hour history of worsening breathlessness and wheeze. She has a history of asthma and uses beclometasone 200 micrograms twice daily and salbutamol as required. On examination, she is unable to complete sentences, her respiratory rate is 32/min, heart rate 125 bpm, oxygen saturation 90% on room air, and PEFR is 35% of her best. She has widespread wheeze bilaterally. She is treated with oxygen, nebulised salbutamol and ipratropium, and oral prednisolone. What is the most appropriate next step in management?
A. Arrange urgent intensive care assessment
B. Administer intravenous magnesium sulphate (Correct Answer)
C. Give intravenous aminophylline infusion
D. Commence bilevel positive airway pressure (BiPAP)
E. Administer subcutaneous adrenaline
Explanation: ***Administer intravenous magnesium sulphate***
- This patient presents with **life-threatening asthma** features, including inability to complete sentences, SpO2 90%, and PEFR 35%, despite initial nebulized bronchodilators and oral steroids.
- According to **BTS/SIGN guidelines**, intravenous **magnesium sulphate** (1.2–2g infusion) is the next step for acute severe or life-threatening asthma that is not responding adequately to initial therapy.
*Arrange urgent intensive care assessment*
- While this patient's condition is severe and might warrant ICU, **IV magnesium sulphate** is a crucial therapeutic intervention to be administered promptly prior to or concurrently with ICU assessment.
- Referral to ICU is typically considered if there's no response to maximal medical therapy, impending respiratory arrest, **exhaustion**, or a **silent chest**.
*Give intravenous aminophylline infusion*
- **Aminophylline** (a methylxanthine) is considered a third-line agent in severe asthma, usually after **intravenous magnesium sulphate** has been tried and failed.
- It has a narrow therapeutic window and higher risk of side effects, requiring careful monitoring, which makes it less favorable than magnesium sulphate as the immediate next step.
*Commence bilevel positive airway pressure (BiPAP)*
- **BiPAP** is generally not recommended for routine use in **acute asthma exacerbations**, as it can worsen air trapping and dynamic hyperinflation.
- In severe asthma not responding to medical therapy, the next step after maximal non-invasive treatment is typically **endotracheal intubation** and mechanical ventilation, not BiPAP.
*Administer subcutaneous adrenaline*
- **Subcutaneous adrenaline** is primarily indicated for **anaphylaxis** or in cases of severe bronchospasm where other routes of administration are not feasible.
- This patient's presentation is consistent with an **acute asthma exacerbation**, for which **intravenous magnesium sulphate** is the more appropriate and evidence-based next step for bronchodilation.
Question 59: A 52-year-old woman presents with a 5-day history of productive cough, fever, and right-sided pleuritic chest pain. She has no comorbidities. Observations: temperature 38.2°C, HR 92/min, BP 128/76 mmHg, RR 20/min, SpO2 96% on air. She is alert (AMT 10/10). Blood tests show urea 5.8 mmol/L. Chest X-ray confirms right middle lobe consolidation. According to NICE guidelines, what is the most appropriate initial antibiotic treatment?
A. Oral amoxicillin 500mg three times daily for 5 days (Correct Answer)
B. Oral doxycycline 200mg loading dose then 100mg daily for 5 days
C. Oral amoxicillin 500mg three times daily plus oral clarithromycin 500mg twice daily for 5 days
D. IV co-amoxiclav 1.2g three times daily plus IV clarithromycin 500mg twice daily
E. Oral levofloxacin 500mg once daily for 5 days
Explanation: ***Oral amoxicillin 500mg three times daily for 5 days***
- The patient has a **CURB-65 score of 0** (no confusion, urea 5.8 mmol/L, RR 20/min, BP 128/76 mmHg, age 52), indicating **low-severity community-acquired pneumonia (CAP)**.
- According to **NICE guidelines**, **oral amoxicillin** for 5 days is the recommended first-line antibiotic treatment for adults with low-severity CAP, primarily targeting *Streptococcus pneumoniae*.
*Oral doxycycline 200mg loading dose then 100mg daily for 5 days*
- **Doxycycline** is considered an alternative first-line treatment for low-severity CAP, particularly for patients with a **penicillin allergy** or when **atypical pathogens** are strongly suspected.
- In this case, no penicillin allergy is mentioned, making amoxicillin the preferred initial choice.
*Oral amoxicillin 500mg three times daily plus oral clarithromycin 500mg twice daily for 5 days*
- This **combination therapy** (beta-lactam plus macrolide) is recommended by NICE for **moderate-severity CAP**, typically indicated by a **CURB-65 score of 2**.
- For a patient with low-severity CAP (CURB-65 score 0), this dual regimen is unnecessarily broad-spectrum and increases the risk of side effects and antibiotic resistance.
*IV co-amoxiclav 1.2g three times daily plus IV clarithromycin 500mg twice daily*
- **Intravenous (IV) antibiotics** and broad-spectrum combinations are reserved for **high-severity CAP** (CURB-65 score 3-5) or patients who cannot tolerate oral medication.
- Given the patient's low CURB-65 score and ability to take oral medication, IV treatment is not indicated.
*Oral levofloxacin 500mg once daily for 5 days*
- **Fluoroquinolones** like levofloxacin are generally reserved for patients with severe allergies to first-line agents, for moderate-severity CAP as an alternative, or in cases of treatment failure.
- Their use as initial empirical therapy for low-severity CAP is discouraged due to concerns about **antibiotic resistance** and potential side effects such as *Clostridioides difficile* infection.
Question 60: A 71-year-old man with known COPD (FEV1 40% predicted) on home oxygen presents with acute confusion, drowsiness, and headache. His wife reports he increased his oxygen from 2L/min to 6L/min this morning due to increased breathlessness. Observations: GCS 13 (E3, V4, M6), RR 12/min, HR 88/min, BP 145/82 mmHg. Arterial blood gas on 6L/min oxygen shows: pH 7.19, PaCO2 9.8 kPa, PaO2 13.2 kPa, HCO3- 35 mmol/L, BE +8. What is the most important immediate management step?
A. Continue current oxygen therapy and commence IV doxapram
B. Reduce oxygen to 28% venturi mask targeting saturations 88-92% (Correct Answer)
C. Commence non-invasive ventilation immediately
D. Reduce oxygen and give naloxone 400 micrograms IV
E. Intubate and commence mechanical ventilation
Explanation: ***Reduce oxygen to 28% venturi mask targeting saturations 88-92%***- The patient is experiencing **iatrogenic hypercapnic respiratory failure** (CO2 narcosis) due to excessive oxygen administration, which worsens **V/Q mismatch** and the **Haldane effect** in COPD.- The most critical immediate step is to **reduce oxygen delivery** to a controlled level (e.g., 24-28% Venturi mask) to target saturations of **88-92%**, which will help decrease PaCO2 and improve the patient's neurological status.*Continue current oxygen therapy and commence IV doxapram*- Continuing high-flow oxygen would further exacerbate the **hypercapnia** and **respiratory acidosis**, potentially leading to respiratory arrest and deeper coma.- **Doxapram** is a respiratory stimulant that is rarely used today due to limited efficacy and side effects, having been largely replaced by **non-invasive ventilation (NIV)** when pharmacological stimulation is considered.*Commence non-invasive ventilation immediately*- While **NIV** may be required if the patient does not improve with oxygen reduction, the most immediate and appropriate first step for **oxygen-induced hypercapnia** is to correct the iatrogenic cause by titrating oxygen.- Many patients with **oxygen-induced hypercapnia** will significantly improve with proper oxygen management alone, thereby potentially avoiding the need for immediate NIV.*Reduce oxygen and give naloxone 400 micrograms IV*- While reducing oxygen is correct, there is **no clinical indication for naloxone** as there is no history or physical findings suggestive of **opioid overdose**.- The patient's acute confusion and drowsiness are consistent with **CO2 narcosis** from hypercapnia, not opioid toxicity.*Intubate and commence mechanical ventilation*- **Intubation** and **mechanical ventilation** are highly invasive interventions associated with significant risks in COPD patients and should be reserved as a **last resort** when less invasive measures, such as oxygen titration and NIV, have failed.- The primary goal is to stabilize the patient using the **least invasive approach** first, starting with correcting the excessive oxygen.
